The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 4)
Target Advancement Program, 2016
Loss-of-function GBA1 mutations in Gaucher disease result in increased risk for Parkinson's disease (PD). Glucocerebrosidase (GCase) normally breaks down a lipid called glucosylceramide (GluCer) that accumulates due to decreased GCase activity. Previous data have indicated that GluCer directly interacts with alpha-synuclein, the main component of Lewy body inclusions; the GluCer-al...
Researchers: Joseph R. Mazzulli, PhD
MJFF Research Grant, 2011
A measurement tool which accurately reflects not only motor deficits but also a host of cognitive dysfunctions seen frequently in Parkinson's disease (PD) would improve diagnosis of the disease and identify PD subtypes for more effective tailored treatment strategies.
We propose that an assessment of motor and cognitive deficits in PD together will lea...
Researchers: Norbert Schuff, PhD
Promising Outcomes of Original Grant:
As Parkinson's disease is diagnosed when already a number of neurons have degenerated the PRIPS cohort consisting of 1847 healthy subjects older than 50 years was established to assess PD risk markers before motor dysfunction becomes evident. At the first investigation (baseline) among others the putative premotor markers substantia nigra hyperechogenictiy (SN...
The development of disease-course modifying or neuroprotective treatments is still an unmet therapeutical need in Parkinson's disease. Treatment will likely work best if initiated as early as possible. There is ample evidence to suggest that PD is present in "latent" or "preclinical" form many years before the onset of classical motor symptoms. The current project is aimed to...